CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...
NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...
Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...
Morning Overview on MSN
One CRISPR shot cut 'bad' cholesterol in half and it lasted a full year
A single intravenous infusion of an experimental CRISPR-Cas9 therapy cut LDL cholesterol by 52.5% in patients who received ...
Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
In CRISPR gene editing, guide RNA (gRNA) directs the Cas9 complex to its target. Impurities introduced during gRNA synthesis ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.
Most of any gains (or lack thereof) from here will be driven by just three factors.
A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results